| Name | Title | Contact Details |
|---|
Outbound AI is Conversation AI built for healthcare. Founded in 2021, the Seattle-based startup is breaking new ground with cloud technologies that serve as workforce multipliers to drive productivity while improving the daily job experience for human talent. The company`s inaugural offering includes a portfolio of intelligent Virtual Agents specially trained to streamline phone-based administrative work across the revenue cycle, including claims status, eligibility and benefits verification, prior authorization and more. Outbound AI is led by a passionate team of health and voice tech veterans and backed by several preeminent venture capital firms.
DVM Resources is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Kiwi-Tek is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Life Technologies Corp., (NASDAQ: LIFE) www.lifetechnologies.com - On November 21, 2008, Invitrogen Corporation and Applied Biosystems Inc announced the completion of their merger transaction. Effective November 24, 2008, the two companies merged to form a new company under the name, Life Technologies Corporation
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.